PriceTargets.com logo

Cardiol Therapeutics - CRTPF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.77 As of 04/19/2024 01:00 AM ET
▲ +0.1 (5.99%)

This chart shows the closing price for CRTPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardiol Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRTPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRTPF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.77.

This chart shows the closing price for CRTPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cardiol Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/17/2022Raymond JamesDowngradeOutperform ➝ Market Perform
5/17/2021Raymond JamesBoost TargetOutperformC$4.25 ➝ C$4.50
4/29/2021Raymond JamesUpgradeMarket Perform ➝ Outperform
(Data available from 4/20/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cardiol Therapeutics logo
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
Read More

Today's Range

Now: $1.77
Low: $1.55
High: $1.79

50 Day Range

MA: $1.64
Low: $1.02
High: $2.06

52 Week Range

Now: $1.77
Low: $1.48
High: $4.19

Volume

567,455 shs

Average Volume

67,097 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiol Therapeutics?

The following Wall Street sell-side analysts have issued reports on Cardiol Therapeutics in the last twelve months:
View the latest analyst ratings for CRTPF.

What is the current price target for Cardiol Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cardiol Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cardiol Therapeutics in the next year.
View the latest price targets for CRTPF.

What is the current consensus analyst rating for Cardiol Therapeutics?

Cardiol Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CRTPF.

What other companies compete with Cardiol Therapeutics?

Other companies that are similar to Cardiol Therapeutics include 1933 Industries, 4Cable TV International, 4Front Ventures, AB Science and Abacus Health Products. Learn More about companies similar to Cardiol Therapeutics.

How do I contact Cardiol Therapeutics' investor relations team?

The company's listed phone number is (289) 910-0850. The official website for Cardiol Therapeutics is www.cardiolrx.com. Learn More about contacing Cardiol Therapeutics investor relations.